Efficacy of povidone iodine spray for SARS-CoV-2 eradication in upper respiratory tract of patients with COVID-19: A pilot study
Phase 3
Completed
- Conditions
- Asymptomatic infection or mild symptoms of COVID-19 confirmed by real-time polymerase chain reaction (RT-PCR)SARS-CoV-2, COVID-19, povidone iodine, upper respiratory tract
- Registration Number
- TCTR20210125002
- Lead Sponsor
- Health System Research Institute (HSRI)
- Brief Summary
0.4% PVP-I nasal spray demonstrated minimal virucidal efficacy at 3 minutes post-exposure. At 4 hours post-exposure, the viral titer was unchanged from baseline. The poor virucidal activity of 0.4% PVP-I nasal spray is unlikely to reduce transmission of SARS-CoV-2. The 0.4% PVP-I nasal spray was well-tolerated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
1. Age 18-60 years,
2. Asymptomatic or mild symptom of COVID-19 by RT-PCR,
3. Willing to participate in the present study,
4. Cycle threshold of RT-PCR for SARS-CoV-2 less than 25 (within 3 days before enrollment)
Exclusion Criteria
1. Severe allergy to seafood or iodine,
2. Pregnancy or lactation,
3. Thyroid gland enlargement or thyrotoxicosis,
4. Receiving favipiravir or remdesivir treatment before enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viral culture 3 minutes after administration Growth
- Secondary Outcome Measures
Name Time Method Viral culture 4 hours after administration Growth,RT-PCR 3 minutes after administration Cycle threshold,RT-PCR 4 hours after administration Cycle threshold,Adverse event During and 4 hours after administration Presence